Finally we turn to our IMPEDE Technology that is used in methamphetamine resistant pseudoephedrine products. In 2015 we entered into a research collaboration with Bayer Healthcare to develop an IMPEDE Technology pseudoephedrine product for them for the US market. We continue to execute under that agreement.
Hi, I figured how to follow up just in case everyone was just listening to intently. Are you allowed to comment any further about the [Bayer] Pharma relationship at this time?
Bob Jones
No, but [Bayer] for competitive reasons really doesn’t want information or wants minimal information out. So, we’ve not disclosed the product that we’re working on with them and at this point we’re not disclosing how quickly that research is advancing or where it is in its development stage. My guess to just provide some comfort level and some color on it. The product that we’re working on with them we on the Acura side have not found any significant impediments to advancing that project and it’s going well from our perspective.
This is really a true collaboration with [Bear] so our scientists and development team are taking the product to a certain level. Obviously, we’ve disclosed it, it involves [indiscernible] containing products and of course it’s RMP technology that we bring to the table. [Bear] brings their knowledge of that particular product that we’re trying to formulate with IMPEDE. So it really is a collaboration so you should understand it, it’s where we’re taking the product, doing some work, handing it back to them, they’re doing some work, it’s a back and forth. So that kind of nature of this, it really is true collaboration.
